Navigation Links
Stemedica and Scripps to Jointly Investigate Therapeutic Effect of Ischemia Tolerant Mesenchymal Stem Cells (itMSC) and Stem Cell Factors in Lung Injury and Sepsis
Date:12/21/2012

nhance bacterial clearance in clinically relevant models of bacterial pneumonia in mice. These beneficial effects have also been achieved using human MSCs in an ex-vivo human lung model of ALI.

Naveen Gupta, MD, Assistant Professor of Molecular and Experimental Medicine and Principal Investigator at The Scripps Research Institute, has authored and co-authored a number of publications in peer-reviewed journals in this field. He commented that, “This project will investigate the therapeutic effects of Stemedica’s ischemia tolerant MSCs in experimental lung injury and sepsis. Specifically, it will determine the optimal route, dose and timing of cell delivery in an E. coli pneumonia model. In addition, studies will be done using purified soluble factors secreted by the stem cells to determine whether a therapeutic effect comparable to using live MSCs can be achieved.” Dr. Gupta continued: “Given Stemedica's expertise in the field of developing MSC-based clinical therapies and the scientific and clinical expertise in Pulmonary and Critical Care Medicine present at Scripps, I believe that this will be a mutually beneficial and productive collaboration that may have important implications in how cell based therapy is applied to critically ill patients.”

Nikolai Tankovich, M.D., Ph.D., President and Chief Medical Officer of Stemedica noted, “One of the great advantages of using Stemedica’s cGMP produced, FDB licensed (Food & Drug Branch of the California Department of Public Health) stem cells is that they have already been approved by the Food and Drug Administration for use in a variety of clinical trials. The same cGMP manufactured cell can be used in all phases of the approval process from preclinical through clinical trials and ultimately to commercialization. This will contribute significantly to accelerating the process from benchtop to bedside.”

Maynard Howe, Ph.D., Vice Chairman and Chief Executive Officer of Stemedica comment
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Scripps Florida scientists create new approach to destroy disease-associated RNAs in cells
2. Scripps Florida scientists develop new compound that reverses fatty liver disease
3. Scripps Florida scientist awarded $2.5 million to study inner workings of memory formation
4. Scripps Florida scientists uncover a novel cooperative effort to stop cancer spread
5. Scripps Research Institute study points to potential new therapies for cancer and other diseases
6. 2 Scripps Research Institute scientists honored by American Chemical Society
7. Scripps studies show community-based diabetes programs are key to lowered costs and improved care
8. Scripps Research Institute receives $20 million to shed light on HIV drug resistance
9. Scripps Research Institute scientists show protein linked to hunger also implicated in alcoholism
10. Scripps Research scientists devise powerful new method for finding therapeutic antibodies
11. Clinical trials start for stroke drug developed by Scripps Research, USC, and ZZ Biotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... The United States is now mandating that all ... Africa land at one of five airports equipped ... In a statement released Tuesday, Homeland Security ... air passengers from Guinea, Liberia and Sierra Leone ... -- New York City,s Kennedy International Airport, Washington ...
(Date:10/22/2014)... October 22, 2014 The ... which is dedicated to distribute health information technology ... delivery worldwide announced the development of six key ... expect when receiving healthcare. These are an expansion ... care: “providing care that is respectful of and ...
(Date:10/22/2014)... Washington, D.C. (PRWEB) October 22, 2014 With ... November, a national survey by the American Institutes for Research ... they know how to use health insurance, but 42 percent ... review a plan’s details before signing up for coverage. , ... literacy, with only 20 percent able to calculate correctly how ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Best Cheap ... in the world. The site has recently announced that ... hosting supplier for people from around the world. , ... in operation today and is providing various kinds of ... the company insists on offering excellent customer service and ...
(Date:10/22/2014)... October 22, 2014 Losing Weight Your Body’s ... is staring you in the face, it certainly can be ... do your body an extra favor by doing it the ... crash diets. Instead, listen to your body, exercise regularly, and ... is essential to losing weight; you need to exercise more ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2
... /PRNewswire/ - Apotex today issued the following statement concerning an ... , , The Import Alert recently posted by FDA ... This alert relates to observations made following routine audits for ... with the FDA to resolve the identified concerns as quickly ...
... , , THOUSAND OAKS, Calif., ... in the Thomas Weisel Healthcare Conference on Friday, Sept. 11, 2009, ... Eastern Time. Roy Baynes, M.D. Ph.D., vice president of Global ... the presentation will be available over the Internet and can be ...
... , , HOPKINTON, Mass., Sept. ... today announced that Kevin Hrusovsky, President and CEO, will present at ... Tuesday, September 22, 2009 at 11:00 a.m. EDT. , ... be accessed at http://cc.talkpoint.com/ubsx001/092109a_ke/?entity=102_OHYDDUN . The replay of ...
... , Expanding facility will provide training for health ... area of the Bronx , , BRONX, N.Y., ... the newest addition to the non-profit agency on September 10, 2009 ... at the facility. Located at 1438 Ogden Ave., over 9,000 ...
... risk factors early on, researchers say , TUESDAY, Sept. 8 ... people with cystic fibrosis greatly increases their chances of developing ... an inherited disorder that can lead to deadly lung infections ... of the 30,000 people in the United States with the ...
... Combined efforts mean even stronger support for blood safety ... , WASHINGTON, Sept. 8 Safe Blood for Africa ... agreement to provide even stronger support for blood safety and donor programs ... diligently to support blood safety and blood donor programs throughout Africa. Hema-Quebec ...
Cached Medicine News:Health News:Amgen to Present at the Thomas Weisel Healthcare Conference 2Health News:Highbridge Community Life Center Grand Opening and Ribbon Cutting Ceremony for New Health Careers/Education Facility in the Bronx 2Health News:Gene Linked to Liver Disease in Cystic Fibrosis 2Health News:Safe Blood for Africa Foundation and Hema-Quebec Sign Far-Reaching Agreement 2
(Date:10/22/2014)... LA JOLLA, Calif. , Oct. 22, ... RGLS ), a biopharmaceutical company leading ... targeting microRNAs, today announced that it has ... from an ongoing clinical study evaluating RG-101, ... for the treatment of hepatitis C virus ...
(Date:10/20/2014)...  PneumRx, Inc. ( www.pneumrx.com ), a leader in ... enrollment in their RENEW Study, nearly 3 months ahead ... IDE pivotal trial for the PneumRx RePneu Coil System, ... anticipated that the study, which began enrolling subjects in ... end of 2014 to enroll 315 patients.  Instead, enrollment ...
(Date:10/20/2014)... 2014  Indianapolis interventional medical device maker ... -based 3D visualization leader Synaptive Medical ... Annual Meeting that they have joined forces to ... collaboration is the first of its kind and ... outcomes. NICO,s BrainPath® interventional access technology and Synaptive,s ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5
... Inc. (OTCPK: SNDY) is pleased to announce that the Company ... in the amount of $90,005. The revenue for the three ... fifty Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers ... growth in 2011 through new product development, new product sales ...
... Ireland, Jan. 27, 2011 Tibotec Pharmaceuticals today ... to generic manufacturers including Hetero Drugs Limited, Matrix ... Aspen Pharmacare of South Africa to manufacture, market ... rilpivirine hydrochloride (TMC278), pending ...
Cached Medicine Technology:Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010 2Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 2Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 3Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 4
The double beveled oblique blade provides a true, straight incision. Penetrating through Bowman's and Descemet's membranes without inducing corneal distortion. No need to "Dimple Down"....
... The Boomerang ClosureWire Vascular Closure System ... Arteriotomy Site-Specific Compression., ,The Boomerang ClosureWire ... the inside of the arteriotomy and ... in a targeted internal compression of ...
... The new hand-held Slit Lamp HSL150 with ... filter For Human and Veterinary medicine for ... With an ergonomic, compact,design, the new HEINE ... a,standard slit lamp is not available,or practical ...
... Geriatrics At Your Fingertips ... geriatrics that provides up-to-date, practical information on ... disorders most common to elderly people. Updated ... the GAYF web site, where versions for ...
Medicine Products: